AKT1 and neoplasm: Considering the role of MAPK and AKT/PI3K pathways in the progression of DTC, Yarchoan et al. investigated the molecular tumor markers from these two pathways in a phase 2 study evaluating the effectiveness of sorafenib in the treatment of RR-DTC.